

REMARKS

Claims 1-20, 31 and 32 are pending. Claims 1, 12, 19 and 32 are currently amended. New claims 33-42 are added. Reconsideration of the application in view of the amendments above and remarks below is requested. No new matter has been added.

I. The Objection to Claims 30, 31, 32,

Claims 30 and 31 are canceled. Reconsideration is urged.

Applicants traverse the objection to claim 32. Magnesium sulfate or hydrated magnesium sulfate are narrower terms than magnesium salt. Applicants should be able to include a narrower claim to protect their invention. Reconsideration is urged.

II. The Rejection of Claims 1-11, 14-20 and 28 under 35 U.S.C. 102(e)/103

Claims 1-11, 14-20 and 28 stand rejected under 35 U.S.C. 102(e)/103 as allegedly anticipated or obvious in light of U.S. Patent No. 7,070,820 (hereinafter referred to simply as "Simonsen").

Claims 1 is currently amended to include magnesium salt. Reconsideration and withdrawal of the rejection is urged.

III: New Claims

New claims 33-42 are added. Should any additional fees be due, the USPTO is authorized to charge the Deposit Account of Novozymes North America, Inc.-- Deposit Account No. 50-1701.

IV. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: April 17, 2008

/Michael W. Krenicky Reg. # 45411/
Michael W. Krenicky Reg. No. 45,411
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097